{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,19]],"date-time":"2026-01-19T02:04:19Z","timestamp":1768788259279,"version":"3.49.0"},"reference-count":28,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,7,12]],"date-time":"2021-07-12T00:00:00Z","timestamp":1626048000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Regulatory Toxicology and Pharmacology"],"published-print":{"date-parts":[[2021,10]]},"DOI":"10.1016\/j.yrtph.2021.104985","type":"journal-article","created":{"date-parts":[[2021,7,5]],"date-time":"2021-07-05T01:28:38Z","timestamp":1625448518000},"page":"104985","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"special_numbering":"C","title":["Nonclinical genotoxicity and carcinogenicity profile of apremilast, an oral selective inhibitor of PDE4"],"prefix":"10.1016","volume":"125","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2024-2280","authenticated-orcid":false,"given":"Teresa","family":"Wegesser","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aldo","family":"Coppi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"suffix":"Jr.","given":"Tod","family":"Harper","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria","family":"Paris","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sheroy","family":"Minocherhomji","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.yrtph.2021.104985_bib29","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1016\/0165-1161(75)90046-1","article-title":"Methods for detecting carcinogens and mutagens with the Salmonella\/mammalian-microsome mutagenicity test","volume":"31","author":"Ames","year":"1975","journal-title":"Mutat. Res."},{"key":"10.1016\/j.yrtph.2021.104985_bib22","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1080\/17460441.2016.1184642","article-title":"The discovery of roflumilast for the treatment of chronic obstructive pulmonary disease","volume":"11","author":"Cazzola","year":"2016","journal-title":"Expert Opin. Drug Discov."},{"key":"10.1016\/j.yrtph.2021.104985_bib31","author":"CDER Tertiary Pharmacology Review of Apremilast","year":"2014"},{"key":"10.1016\/j.yrtph.2021.104985_bib34","author":"CDER Tertiary Pharmacology Review of Roflumilast","year":"2011"},{"key":"10.1016\/j.yrtph.2021.104985_bib1","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1111\/j.1745-7270.2008.00438.x","article-title":"Epac and PKA: a tale of two intracellular cAMP receptors","volume":"40","author":"Cheng","year":"2008","journal-title":"Acta Biochim. Biophys. Sin."},{"key":"10.1016\/j.yrtph.2021.104985_bib2","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1016\/j.jdermsci.2017.03.020","article-title":"2-Year animal carcinogenicity results for crisaborole, a novel phosphodiesterase 4 inhibitor for atopic dermatitis","volume":"87","author":"Ciaravino","year":"2017","journal-title":"J. Dermatol. Sci."},{"key":"10.1016\/j.yrtph.2021.104985_bib32","author":"Daliresp [Package Insert]","year":"2017"},{"key":"10.1016\/j.yrtph.2021.104985_bib3","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1016\/S0940-2993(01)80002-6","article-title":"Tumors in long-term rat studies associated with microchip animal identification devices","volume":"52","author":"Elcock","year":"2001","journal-title":"Exp. Toxicol. Pathol."},{"key":"10.1016\/j.yrtph.2021.104985_bib4","doi-asserted-by":"crossref","first-page":"965","DOI":"10.1016\/S0006-2952(98)00331-1","article-title":"Cyclic nucleotide phosphodiesterase (PDE) inhibitors and immunomodulation","volume":"57","author":"Essayan","year":"1999","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.yrtph.2021.104985_bib5","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1067\/mai.2001.119555","article-title":"Cyclic nucleotide phosphodiesterases","volume":"108","author":"Essayan","year":"2001","journal-title":"J. Allergy Clin. Immunol."},{"key":"10.1016\/j.yrtph.2021.104985_bib33","author":"Eucrisa [Package Insert]","year":"2020"},{"key":"10.1016\/j.yrtph.2021.104985_bib6","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/0165-1161(79)90135-3","article-title":"Application of a simple giemsa-staining method in the micronucleus test","volume":"64","author":"Gollapudi","year":"1979","journal-title":"Mutat. Res."},{"key":"10.1016\/j.yrtph.2021.104985_bib7","doi-asserted-by":"crossref","first-page":"1918","DOI":"10.1056\/NEJMoa1816594","article-title":"Trial of apremilast for oral ulcers in Beh\u00e7et's syndrome","volume":"381","author":"Hatemi","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.yrtph.2021.104985_bib8","doi-asserted-by":"crossref","first-page":"105134","DOI":"10.1016\/j.phrs.2020.105134","article-title":"The immunomodulatory role of PDEs inhibitors in immune cells: therapeutic implication in rheumatoid arthritis","volume":"161","author":"He","year":"2020","journal-title":"Pharmacol. Res."},{"key":"10.1016\/j.yrtph.2021.104985_bib9","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1034\/j.1399-3003.2000.15b21.x","article-title":"Phosphodiesterase and cyclic adenosine monophosphate-dependent inhibition of T-lymphocyte chemotaxis","volume":"15","author":"Hidi","year":"2000","journal-title":"Eur. Respir. J."},{"key":"10.1016\/j.yrtph.2021.104985_bib10","first-page":"1","author":"ICHS2(R1)","year":"2011"},{"key":"10.1016\/j.yrtph.2021.104985_bib11","first-page":"197","article-title":"Phosphodiesterase 4 and its inhibitors in inflammatory diseases","volume":"35","author":"Jin","year":"2012","journal-title":"Chang Gung Med. J."},{"key":"10.1016\/j.yrtph.2021.104985_bib12","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1186\/1741-7015-11-96","article-title":"Phosphodiesterase 4-targeted treatments for autoimmune diseases","volume":"11","author":"Kumar","year":"2013","journal-title":"BMC Med."},{"key":"10.1016\/j.yrtph.2021.104985_bib13","doi-asserted-by":"crossref","first-page":"3791","DOI":"10.1038\/s41388-020-1258-8","article-title":"PDE4 subtypes in cancer","volume":"39","author":"Lai","year":"2020","journal-title":"Oncogene"},{"key":"10.1016\/j.yrtph.2021.104985_bib14","doi-asserted-by":"crossref","first-page":"1048","DOI":"10.3389\/fphar.2018.01048","article-title":"Phosphodiesterase-4 inhibitors for the treatment of inflammatory diseases","volume":"9","author":"Li","year":"2018","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.yrtph.2021.104985_bib15","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1016\/j.pharmthera.2005.07.003","article-title":"Cyclic nucleotide phosphodiesterase (PDE) superfamily: a new target for the development of specific therapeutic agents","volume":"109","author":"Lugnier","year":"2006","journal-title":"Pharmacol. Ther."},{"key":"10.1016\/j.yrtph.2021.104985_bib16","doi-asserted-by":"crossref","first-page":"1522","DOI":"10.1021\/jm900210d","article-title":"Discovery of (S)-N-[2-[1-(3-ethoxy-4-methoxyphenyl)-2-methanesulfonylethyl]-1,3-dioxo-2,3-dihydro-1H-isoindol-4-yl] acetamide (apremilast), a potent and orally active phosphodiesterase 4 and tumor necrosis factor-alpha inhibitor","volume":"52","author":"Man","year":"2009","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.yrtph.2021.104985_bib17","doi-asserted-by":"crossref","first-page":"1393","DOI":"10.1038\/sj.bjp.0702911","article-title":"Suppression of human inflammatory cell function by subtype-selective PDE4 inhibitors correlates with inhibition of PDE4A and PDE4B","volume":"128","author":"Manning","year":"1999","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.yrtph.2021.104985_bib18","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1038\/nrd4228","article-title":"Advances in targeting cyclic nucleotide phosphodiesterases","volume":"13","author":"Maurice","year":"2014","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.yrtph.2021.104985_bib30","author":"Otezla [Package Insert]","year":"2020"},{"key":"10.1016\/j.yrtph.2021.104985_bib19","doi-asserted-by":"crossref","first-page":"1583","DOI":"10.1016\/j.bcp.2012.01.001","article-title":"Apremilast mechanism of action and application to psoriasis and psoriatic arthritis","volume":"83","author":"Schafer","year":"2012","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.yrtph.2021.104985_bib20","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1007\/s40268-019-00284-1","article-title":"Apremilast normalizes gene expression of inflammatory mediators in human keratinocytes and reduces antigen-induced atopic dermatitis in mice","volume":"19","author":"Schafer","year":"2019","journal-title":"Drugs R"},{"key":"10.1016\/j.yrtph.2021.104985_bib21","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1016\/j.cellsig.2016.01.007","article-title":"Phosphodiesterase 4 in inflammatory diseases: effects of apremilast in psoriatic blood and in dermal myofibroblasts through the PDE4\/CD271 complex","volume":"28","author":"Schafer","year":"2016","journal-title":"Cell. Signal."}],"container-title":["Regulatory Toxicology and Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0273230021001264?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0273230021001264?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,3]],"date-time":"2025-10-03T12:32:25Z","timestamp":1759494745000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0273230021001264"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,10]]},"references-count":28,"alternative-id":["S0273230021001264"],"URL":"https:\/\/doi.org\/10.1016\/j.yrtph.2021.104985","relation":{},"ISSN":["0273-2300"],"issn-type":[{"value":"0273-2300","type":"print"}],"subject":[],"published":{"date-parts":[[2021,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Nonclinical genotoxicity and carcinogenicity profile of apremilast, an oral selective inhibitor of PDE4","name":"articletitle","label":"Article Title"},{"value":"Regulatory Toxicology and Pharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.yrtph.2021.104985","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Amgen Inc. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"104985"}}